Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Boston Scientific (BSX)

Boston Scientific Q1 sales rise 11.6% to $5.203 billion; adjusted EPS $0.80

Positive Impact 3 of 5 earnings Written later

Boston Scientific reported first quarter 2026 net sales of $5.203 billion, up 11.6% on a reported basis and 9.4% on an organic basis from $4.663 billion a year earlier. GAAP diluted EPS was $0.90, versus $0.45, and adjusted EPS was $0.80, versus $0.75, with the adjusted figure at the top of the company's $0.78 to $0.80 guidance range. The company also issued updated 2026 outlook figures, including adjusted EPS of $3.34 to $3.41 for the full year and $0.82 to $0.84 for the second quarter.

Key points

  • Net sales of $5.203 billion rose 11.6% reported and 9.4% organic; Cardiovascular grew 13.5% and MedSurg grew 7.8%.
  • GAAP diluted EPS was $0.90 versus $0.45; the filing's reconciliation shows a $320 million deferred tax benefit excluded from adjusted results.
  • Adjusted EPS was $0.80 versus $0.75 a year ago and within the $0.78 to $0.80 guidance range.
  • Updated outlook: full-year 2026 reported net sales growth of 7.0% to 8.5% and adjusted EPS of $3.34 to $3.41; second-quarter adjusted EPS of $0.82 to $0.84.

The filing

CompanyBoston Scientific (BSX)
Form8-K, current report
Filed with the SECApr 22, 2026, 6:34 AM ET
Accession number0000885725-26-000031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.